New Delhi, Feb. 15 -- Sun Pharmaceutical Industries Ltd's founder and managing director Dilip Shanghvi on Tuesday, 12 February, assured investors they have not been "disadvantaged", following serious corporate governance issues that emerged last November. Shanghvi said the company has responded to the Securities and Exchange Board of India (Sebi) that is examining a complaint by a whistle-blower, who had approached the capital markets regulator with a 150-page letter alleging various irregularities by the company, its promoters and others. The letter highlighted Sun Pharma's dealing with subsidiary Aditya Medisales Ltd (AML), a pharmaceutical distribution company classified as a promoter shareholder of Sun Pharma with a stake of 1.6% as of ...